Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of PBC is various from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. The diagnosis of PBC is based on cholestatic biochemical liver tests, presence of antimitochondrial antibody and histologic findings of nonsuppurative destructive cholangitis. Although the diagnosis is straightforward, it could be underdiagnosed because of its asymptomatic presentation, or underrecognition of the disease. UDCA in a dose of 13-15 mg/kg is the widely approved therapy which can improve the prognosis of patients with PBC. However, one-third of patients does not respond to UDCA therapy and may require liver transplantation. 
INTRODUCTION
Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. 1 PBC is characterized by presence of antimichondrial antibody (AMA), histologic findings of portal inflammation and immune-mediated destruction of the intrahepatic bile ducts. It mainly affects middle-aged women. PBC is most prevalent in northern Europe.
The prevalence of PBC differs considerably in different geographic regions, ranging from 40 to 400 per million. 1 The prevalence of PBC in Japan is about from 27 to 54 per million. 2 The prevalence of PBC in Korea has not been investigated, but PBC is designated as one of rare disorders by Korean government. The clinical characteristics of PBC in Korea are similar with those in regions where PBC are prevalent. 3 The manifestations and prognosis are various in different patients. Diagnosis in earlier stage and treatment with ursodeoxycholic acid (UDCA) have improved the prognosis in patients with PBC over the past two decades. This article reviews an overview of the updated knowledge on the diagnosis and treatment of PBC.
NATURAL HISTORY
PBC progresses insidiously through the clinical phases:
preclinical, asymptomatic, symptomatic, and liver insufficiency ( Table 1) . 4 The preclinical phase is characterized by AMA reactivity with no symptom and normal biochemical liver tests.
Then patients develop biochemical abnormalities but remain asymptomatic. The median time to progression from preclinical to asymptomatic phase was 5.6 years (range, 1-20 years).
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Asymptomatic phase is followed by the development of symptoms, usually fatigue and pruritus, and later varices, edema, or ascites in most untreated patients within 2 to 4 years. 6 Liver insufficiency is characterized by accelerated jaundice, and the prognosis is poor. 7 Mean survival in patients with bilirubin level of 2.0 mg/dL is 4 years, and that in patients with bilirubin level of 6.0 mg/dL is 2 years.
The prognosis of patients with PBC has improved significantly over the past 2 decades because more patients are being diagnosed earlier in the disease process 8 and being treated with UDCA.
UDCA therapy significantly delayed histologic progression, 9 decreased the development of esophageal varices, 10 and increased the survival in patients with PBC. [11] [12] [13] The survival rate of patients with early stage (stage 1 or 2 disease) who were treated with UDCA for a mean of eight years was similar to that of a healthy control population. 14 
CLININCAL MANIFESTATIONS
PBC is now diagnosed earlier in its clinical course owing to easy access to biochemical tests and widespread use of the specific AMA assay. More than 50% of patients are asymptomatic at presentation. 3, [15] [16] [17] Sixty percents of patients were asymptomatic at diagnosis also in Korea. 3 The most common symptoms in PBC patients at diagnosis are fatigue and pruritus. Fatigue has been reported in up to 78 percents of patients, [18] [19] [20] and does not appear to correlate with disease severity, histologic stage, or duration, and may impair the quality of life. 20 The etiology of fatigue is unknown, but may be related to autonomic dysfunction. 21 Pruritus, which occurs in 20 to 70 percent of patients, can be the most distressing symptom. 22 The onset of pruritus usually precedes the onset of jaundice by months to years. The pruritus can be local or diffuse. It is usually worse at night and is often exacerbated by contact with wool, other fabrics, or heat. Its cause is unknown, but endogenous opioids may have a role. Unexplained discomfort in the right upper quadrant occurs in approximately 10 percent of patients. 23 Other common findings in primary biliary cirrhosis include hyperlipidemia, hypothyroidism, osteopenia, and coexisting autoimmune diseases such as Sjögren's syndrome and scleroderma. 24 Portal hypertension does not usually occur until later in the course of the disease. Malabsorption, deficiencies of fat-soluble vitamins, and steatorrhea are uncommon except in advanced disease. Rarely, patients present with ascites, hepatic encephalopathy, or hemorrhage from esophageal varices. 25 The incidence of hepatocellular carcinoma is elevated among patients with long-standing advanced disease. 26 Other diseases associated with primary biliary cirrhosis include interstitial pneumonitis, celiac disease, sarcoidosis, renal tubular acidosis, hemolytic anemia, and autoimmune thrombocytopenia.
DIAGNOSIS
The diagnosis of PBC should be suspected in the setting of 
27
Liver biochemical tests 
TREATMENT
Ursodeoxycholic Acid (UDCA)
UDCA, the 7-beta epimer of chenodeoxycholic acid, comprised 2% of human bile acid and has several interrelated functions including direct choleretic, anti-inflammatory, and antiapoptotic
properties. 45 UDCA in a dose of 13-15 mg/kg /day is the only drug approved for PBC treatment by USA FDA (Table 2) . 27 It decreases serum levels of bilirubin, ALP, aminotransferase, cholesterol and IgM, 46, 47 and improves liver histology. 12, 46 A combined analysis of the three largest clinical trials shows that UDCA prolongs survival free of liver transplantation. 48 The adequate dosing of UDCA is important. A dose of 13-15 mg/kg/day was superior to either a lower dose of 5-7 mg/kg/day or a higher dose of 23-25 mg/kg/day in biochemical responses and costs. 49 A complete response occurs in about 30% of patients treated with PBC, which was defined by normalized biochemical tests and stabilized or improved liver histology. 50, 51 Serum ALP levels at 6 months after UDCA therapy can be helpful in predicting response to UDCA. 30, 32 The life expectancy of patients showing the complete response during treatment with UDCA was similar to that of age-and sex-matched healthy controls for up to 20 years. 32 However, the disease progresses in many patients who do not show the complete response during UDCA therapy, for whom additional medical treatment is definitely required.
Other drugs than UDCA Tamoxifen decreased alkaline phosphatase levels in two women who were taking it after surgery for breast cancer. 72 Although atorvastatin with many antiinflammatory properties was commonly used for control of hypercholesterolemia in PBC, it was not effective for PBC itself. 73 
Liver transplantation
Transplantation is the only effective treatment for those with decompensated cirrhosis or liver failure. 74 The outcome of liver transplantation in patients with PBC is more favorable than for other liver diseases. The survival rates at one and five years are 92 percent and 85 percent, respectively. About 20-25% of patients with PBC who undergo transplantation have recurrent disease over 10 years. Fortunately, recurrent PBC does not affect patient or graft survival. 75 
CONCLUSION
The diagnosis of PBC should be suspected in subjects with chronic cholestasis, mainly elevation of ALP after exclusion of other causes of hepatobiliary disease. The diagnosis of PBC is largely confirmed with tests for AMA. AMA is highly specific for the diagnosis of PBC and positive in nearly 95% of patients.
Liver biopsy can be used especially for further evaluation in subjects with negative tests for AMA and suspicious overlap syndrome. UDCA in a dose of 13-15 mg/kg /day is the standard therapy for PBC treatment, however, about 40% of the patients do not respond to UDCA. Therefore, further efforts to develop new drugs and clinical trial should be warranted.
